Growth and Margin Analysis of Syndax Pharmaceuticals Inc (SNDX)’s Recent Quarter Sales

As of right now, Syndax Pharmaceuticals Inc [SNDX] is trading at $15.27, up 3.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SNDX shares have gain 12.69% over the last week, with a monthly amount glided 31.52%, and seem to be holding up well over a long-time horizon.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


On 7, November 2023, Syndax Announces Participation at Stifel Healthcare Conference. In a post published today on Yahoo Finance, Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 4:45 p.m. ET.

From an analyst’s perspective:

Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on October 25, 2023, when BofA Securities initiated its Buy rating and assigned the stock a price target of $29.

Through the last year, Syndax Pharmaceuticals Inc’s stock price ranged from $11.22 to $29.86. Currently, Wall Street analysts expect the stock to reach $35.17 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $15.27 at the most recent close of the market. An investor can expect a potential return of 130.32% based on the average SNDX price forecast.

Analyzing the SNDX fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -31.54, Equity is -34.10, Total Capital is -33.80, and Invested Capital is -33.29. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 0.25 and enduring liabilities to the whole assets at 0.23.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.94 points at the first support level, and at 14.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.48, and for the 2nd resistance point, it is at 15.68.

Syndax Pharmaceuticals Inc [SNDX] reported earnings per share of -$0.73 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.79/share, meaning a difference of $0.06 and a surprise factor of 7.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.64 per share as compared to estimates of -$0.73 per share, a difference of $0.09 representing a surprise of 12.30%.

Ratios To Look Out For

It is important to note that Syndax Pharmaceuticals Inc [NASDAQ:SNDX] has a current ratio of 9.73. Further, the Quick Ratio stands at 16.85, while the Cash Ratio is 16.37.

Transactions by insiders

Recent insider trading involved Morrison Briggs, Director, that happened on Aug 09 when 52855.0 shares were sold. Director, Meury William completed a deal on Aug 02 to sell 83000.0 shares. Meanwhile, Director Morrison Briggs sold 52855.0 shares on Jul 10.